Drug Development

Feliza Mirasol is the science editor for 

Videos

Colin McKinlay, the senior director of Chemistry and Delivery Technologies at Nutcracker Therapeutics, discusses current challenges in mRNA and LNP manufacturing as well as innovations that meet these challenges.

Addressing Challenges in mRNA and LNP Manufacturing (Part One)

Articles

The partners will aim to establish a platform that enables rapid development of DPI products.

Intertek Teams Up with CrystecPharma on Formulation and Development of Dry Powder Inhaler Products

Cheryl Barton is director of PharmaVision, 

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.

European Biotechs Unlocking Parkinson’s Disease

LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.

Exploring Opportunities for LNP Delivery in mRNA

EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.

Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert

With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.

Lonza to Provide Tailored Offering for the Development of Oral Biologics Using Smart Capsules

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies. 

Behind the Headlines: Pandemic Preparedness, Novel mRNA Applications, and More

Datwyler has launched new coated plungers in its NeoFlex line that are suitable for large volume biologics.

Coated Plungers for Large Volume Biologics

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Circio and Certest to Collaborate on LNP Formulations

The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.

Formulation and Drug Delivery